Exelixis throws in the towel on early-stage liver cancer after final readout shows OS flop

The door to a label expansion for Exelixis’ Cabometyx is now fully shut.

Exelixis kept a sliver of hope — however slim — back in the summer of last year, when it posted mixed results from an interim readout of a Phase III trial testing a combination of Cabometyx and Roche’s Tecentriq against Bayer’s Nexavar in previously untreated liver cancer. But the final analysis proved just as disappointing, as the combo was linked to “neither improvement nor detriment in OS.”